Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
published : Today crawled time : 07:00 save search
HanxBio announces the publication of a research paper in Scientific Reports on preclinical evaluation of Narazaciclib for the treatment of acute myeloid leukemia (AML)
Published: 2024-04-23 (Crawled : 07:00) - prnewswire.com
ONTX | $0.9953 -5.61% 1.3M
|
Health Technology
| Email alert
Add to watchlist
publication treatment research preclinical for leukemia
Banking heavyweight Markus Sauerland, former CEO of Nomura Financial Products Europe GmbH, joins NowCM as COO and Co-CEO
Published: 2024-04-23 (Crawled : 07:00) - prnewswire.com
XYF | News | $3.882 -0.46% 310
|
Finance
| Email alert
Add to watchlist
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
| Email alert
Add to watchlist
europe ceo financial
HighByte Announces Series A Raise to Accelerate Growth in Industrial DataOps Market
Published: 2024-04-23 (Crawled : 07:00) - prnewswire.com
IT | $451.54 1.91% 99K
|
Commercial Services
|
| O: 0.5%
H: 0.0%
C: 0.0%
series growth market
Zscaler Research Finds 60% Increase in AI-Driven Phishing Attacks
Published: 2024-04-23 (Crawled : 07:00) - globenewswire.com
ZS | $177.82 4.01% 1.2M
|
Technology Services
|
| O: 0.9%
H: 0.0%
C: 0.0%
research
Teledyne e2v and Airy3D collaboration delivers more affordable 3D vision solutions
Published: 2024-04-23 (Crawled : 07:00) - globenewswire.com
TDY | $409.895 1.44% 120K
|
Electronic Technology
|
| O: 0.36%
H: 0.0%
C: 0.0%
solutions vision collaboration
SFL - Acquisition of two LNG dual-fuel chemical carriers in combination with long term employment
Published: 2024-04-23 (Crawled : 07:00) - globenewswire.com
SFL | $13.005 1.52% 240K
|
Transportation
|
| O: 1.58%
H: 0.0%
C: 0.0%
acquisition
Together Selects nCino to Revolutionise its Lending Business
Published: 2024-04-23 (Crawled : 07:00) - globenewswire.com
NCNO | $29.73 0.3% 310K
|
Technology Services
|
| O: 0.89%
H: 0.0%
C: 0.0%
business
Todays' Top-5
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Published: 2024-04-23 (Crawled : 07:00) - biospace.com/
IBRX | $5.645 14.27% 27M
|
Manufacturing
|
| O: 17.35%
H: 0.0%
C: 0.0%
il-15 anktiva fda agonist approval bladder cancer for
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.56 162.07% 21M
|
AGBA | $2.74 119.2% 52M
|
Finance
CZOO | $9.07 81.76% 22M
|
EDBL | News | $6.56 74.47% 1.8M
|
MTC | $2.21 41.67% 5.6M
|
Technology Services
OPRT | News | $3.12 38.67% 11M
|
Finance
PALI | $6.59 33.67% 23M
|
Manufacturing
VNRX | $0.7945 32.42% 3.1M
|
Health Technology
MLEC | $1.81 29.29% 2.8M
|
n/a
BTCM | $3.45 27.78% 640K
|
Arts, Entertainment, and Recrea...
Your saved searches
Save your searches and get alerts when important news are released.